1. Medtech Insight
  2. >>Archive

Varian introduces second-generation high-field magnetic resonance imaging (MRI)

Varian Associates (US) introduced its second generation high field, whole body MRI system, the Unity Inova. The research unit has been developed by SISCO, the Siemens-Varian joint venture set up in 1990. It incorporates a Varian spectrometer, Siemens' (Germany) Magnetom gradient system and AS25 whole-body actively shielded gradients, and a 4 T magnet from Oxford Magnet Technology - a Siemens-Oxford Instruments (UK) joint venture. The first unit to go on line will be at the Robarts Research Institute, London, Ontario, where it will be used for functional studies of the brain. A second system will be installed at the Brookhaven National Laboratory in New York.

Varian Associates (US) introduced its second generation high field, whole body MRI system, the Unity Inova. The research unit has been developed by SISCO, the Siemens-Varian joint venture set up in 1990. It incorporates a Varian spectrometer, Siemens' (Germany) Magnetom gradient system and AS25 whole-body actively shielded gradients, and a 4 T magnet from Oxford Magnet Technology - a Siemens-Oxford Instruments (UK) joint venture. The first unit to go on line will be at the Robarts Research Institute, London, Ontario, where it will be used for functional studies of the brain. A second system will be installed at the Brookhaven National Laboratory in New York.

Varian took the opportunity to announce a new 80-leaf radiotherapy collimator, which has yet to receive US FDA marketing clearance....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Olympus, Revival Co-Found Swan In $458M Deal, Face Tech and Regulatory Hurdles

 
• By Marion Webb

Olympus and Revival Healthcare Capital have launched Swan Endosurgical in a $458m milestone-based joint venture to develop a robotic platform for endoluminal surgery. The deal combines Olympus’ GI expertise with Revival’s start-up model, but will face technical and regulatory hurdles.

Alternative Funding Sources Emerge Amid Biotech Industry Challenges

 
• By Jo Shorthouse

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

NHS Orders Halt On Unapproved AI Scribes, Vendors Rush To Self-Certify

 
• By Natasha Barrow

NHS England's national chief clinical information officer issued a cease and desist on unapproved ambient voice technology and AI scribes. The move caused confusion among AVT vendors and went beyond joint MHRA/NHS guidance. IMed consultant Ben Austin shares his perspective.